reduction in Prednisolone requirement after Rituximab treatment and the freedom from subsequent AIH flares were also assessed. Figure 1: Changes in prednisolone doses following Rituximab therapy. Figure 2: Kaplan-Meier curve of freedom from flare-up following Rituximab therapy. Results: Among 22 patients, the majority were female (n = 15, 68%) and of Caucasian ethnicity (n = 18, 86%) with a median age at diagnosis of 44 years (range: 19, 79). Mean serum aminotransferase activities (ALT and AST) improved significantly following Rituximab therapy, with this improvement being sustained for the full 24 months of follow up (p < 0.0010). The mean ALT level improved from 167IU/L pre-treatment to 32 IU/L at 24-months post treatment and mean AST level from 127 IU/L at pre-treatment to 29 IU/L at 24- months post treatment (p < 0.001). A trend toward improvement was detected in bilirubin (p = 0.051) and the international normalised ratio (p = 0.068) upon treatment. Immunoglobulin-G (Ig G) level also improved significantly from mean of 18.9g/L pre-treatment to 13.2 g/L at 24 months (p < 0.001). Prednisolone requirement declined significantly by 12 months after treatment (p = 0.009) (Figure 1). The estimated rates of freedom from AIH flarewere 95% and 77% at one and two years, respectively, following the first dose of Rituximab therapy (Figure 2). Conclusion: Rituximab is effective in selected cases of complicated AIH patients, with improvement in biochemical liver enzymes and immunological parameters up to 24-months post-treatment. THU-203 Primary biliary cholangitis in Spain: fewer symptoms and milder disease at presentation, but similar therapeutic response over the years A. Reig 1 , L.P. Llovet 1 , M.R. Gomez 2 , F. Sáez-Royuela 3 , E. Fábrega 4 , J. Salmerón 5 , D. Horta 6 , A. Castano-Garcia 7 , A. Albillos 8 , R.J. Andrade 9 , M. Sala 10 , J.A. Carrión 11 , E.G. Domínguez 12 , N. Chahri 13 , I. Conde 14 , A.G. Moya 15 , M.H. Conde 16 , M. Diago 17 , Grupo del Registro Col-Hai Enfermedades Autoinmunes Y Colestásicas 18 , A. Pares 1 . 1 Hospital Clínic i provincial de Barcelona, Barcelona University, CIBERehd, IDIBAPS, Liver Unit, Spain; 2 Hospital Universitario Virgen del Rocío, CIBERehd, Sevilla, Spain; 3 Hospital Universitario de Burgos, Burgos, Spain; 4 Hospital Marqués de valdecilla Santander, Santander, Spain; 5 Hospital universitario San Cecilio Granada, Granada, Spain; 6 Hospital Mútua Terrassa, Terrassa, Spain; 7 Hospital Universitario Central de Asturias, Oviedo, Spain; 8 Hospital Ramón y Cajal Madrid, Madrid, Spain; 9 Hospital Universitario Virgen de la Victoria, Malaga, Spain; 10 Hospital Germans Trias i Pujol, CIBERehd, Badalona, Spain; 11 Hospital del Mar, IMIM UAB Barcelona, Barcelona, Spain; 12 Hospital Universitario Doce de Octubre, Madrid, Spain; 13 Hospital Universitario Sagrat Cor, Barcelona, Spain; 14 Hospital de la Fe Valencia, Valencia, Spain; 15 Hospital Santa Creu i Sant Pau, Barcelona, Spain; 16 Hospital Universitario Puerta de Hierro, Majadahonda, Spain; 17 Consorcio Hospital General Valencia, Valencia, Spain; 18 AEEH. CIBERehd Email: anna.rg86@gmail.com Background and Aims: Primary biliary cholangitis (PBC) affects mostly women. There are few data on the characteristics of this disease in Spain, so the objective of this study has been to evaluate the presentation, clinical, immunological and biochemical Table: (abstract: THU-203) Periods 06/1979 to 02/2000 03/2000 to 02/2005 03/2005 to 04/2012 05/2012 to 07/2017 p n = 377 n = 377 n = 376 n = 378 Women % 93.9 92.9 92.5 87.3 = 0.007 Age years (IQR) 52(43–60) 54(45–63) 54(47–65) 56(47–66) <0.001 Symptoms % 40.7 36.4 27 23.5 <0.001 Pruritus % 31.1 29.3 18.1 12.5 <0.001 Fatigue % 34.1 21.3 22 16 <0.001 Jaundice % 3.5 3.5 4.3 0,9 <0.001 Xanthelasma % 1.8 1.5 0.8 0 <0.001 Cirrhosis % 9.3 8.9 8.6 9.3 n.s. AMA positive % 89.3 93.1 93.1 91 n.s. ALT UNL 1.89 (1.26–2.89) 1.49 (0.95–2.34) 1.40 (0.82–2.22) 1.29 (0.83–1.98) =0.012 GGT UNL 3.50 (2.32–9.54) 4.39 (1.93–9.05) 3.64 (2.09–7.08) 4.03 (2.13–7.45) n.s AP UNL 2.25 (1.31–4.61) 1.47 (1.07–2.53) 1.49 (1.00–2.36) 1.44 (1.01–2.34) <0.001 Total Bilirubin mg/dL 0.70 (0.56–1.00) 0.60 (0.47–0.80) 0.53 (0.43–0.70) 0.55 (0.40–0.77) n.s. Platelets ui/mm 3 232 (183–274) 238 (205–286) 244 (202–301) 247 (198–289) n.s Global PBC < 0.30% 75.4 77.4 81.1 74.8 n.s IQR: Interquarte range. ALT: alanine aminotransferase; GGT: gamma glutamyltransferase; AP: alkaline phosphatase; UNL: Upper normal levels. POSTER PRESENTATIONS S218 Journal of Hepatology 2018 vol. 68 | S105–S364